MedTrace Logo

Clinical Study of VG161 in the Treatment of Advanced Bone and Soft Tissue Sarcoma

NCT06126510 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-12-24

No results posted yet for this study

Summary

This study plans to use 1.0×108PFU/day per cycle, intratumoral injection administration for 3 consecutive days, and 28 days as a cycle. Tumor imaging evaluation was performed every 8±1 weeks from the first dose of C1D1 until an event that met the criteria for treatment discontinuation occurred.

Conditions

  • Sarcoma

Interventions

DRUG

Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)

VG161:1.0×10\^8PFU/day, intratumoral injection administration for 3 consecutive days, 28 days as a cycle

Sponsors & Collaborators

  • CNBG-Virogin Biotech (Shanghai) Ltd.

    lead INDUSTRY

Principal Investigators

  • Lu Xie, Medical PhD · Peking University People's Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-18
Primary Completion
2025-07-17
Completion
2026-01-17

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06126510 on ClinicalTrials.gov